Oral COVID-19 Antiviral Uptake Among a Highly Vaccinated US Cohort of Adults With SARS-CoV-2 Infection Between December 2021 and October 2022.

Yanhan ShenMcKaylee M RobertsonSarah G KulkarniLaura PuzniakJoann M ZamparoKristen E AllenThomas M PorterSaba A QasmiehChristian GrovAvantika SrivastavaRebecca ZimbaJohn M McLaughlinDenis Nash

Published in: Open forum infectious diseases (2023)

Despite proven effectiveness against severe outcomes, COVID-19 antiviral uptake remains low among those with SARS-CoV-2 infection in the United States. Further outreach to providers and patients to improve awareness of COVID-19 oral antivirals and indications is needed.

Keyphrases

coronavirus disease
sars cov
respiratory syndrome coronavirus
end stage renal disease
newly diagnosed
ejection fraction
randomized controlled trial
chronic kidney disease
systematic review
prognostic factors
early onset
metabolic syndrome
patient reported
weight loss